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Abstract
Tissue hypoxia is a consequence of decreased oxygen levels in different inflammatory conditions, many associated with
mast cell activation. However, the effect of hypoxia on mast cell functions is not well established. Here, we have
investigated the effect of hypoxia per se on human mast cell survival, mediator secretion, and reactivity. Human cord blood
derived mast cells were subjected to three different culturing conditions: culture and stimulation in normoxia (21% O2);
culture and stimulation in hypoxia (1% O2); or 24 hour culture in hypoxia followed by stimulation in normoxia. Hypoxia, per
se, did not induce mast cell degranulation, but we observed an increased secretion of IL-6, where autocrine produced IL-6
promoted mast cell survival. Hypoxia did not have any effect on A23187 induced degranulation or secretion of cytokines. In
contrast, cytokine secretion after LPS or CD30 treatment was attenuated, but not inhibited, in hypoxia compared to
normoxia. Our data suggests that mast cell survival, degranulation and cytokine release are sustained under hypoxia. This
may be of importance for host defence where mast cells in a hypoxic tissue can react to intruders, but also in chronic
inflammations where mast cell reactivity is not inhibited by the inflammatory associated hypoxia.
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Introduction
Mast cells have an important role in many inflammatory
diseases, such as asthma, and they are also involved in response to
infections, tumor progression and in conditions related to ischemia
[1,2]. Mast cells are distributed in all vascularised tissues
throughout the body and more abundantly in tissues exposed to
the environment, i.e., lung, gut and skin. This makes them one of
the first cells exposed to allergens, pollutants and pathogens [3].
Oxygen concentrations may vary in cells and tissue but when the
gradient of partial pressure (pO2) drops below the normal level it is
denoted as hypoxic [4]. As a result of the reduced oxygen levels in
tissue the metabolism is shifted to consume less oxygen and at the
same time erythropoiesis and angiogenesis are induced to restore
the limited blood supply [5]. Hypoxia is a prominent feature of
inflamed tissues; including tumors, myocardial infarcts, atheroscle-
rotic plaques, lung of asthmatics, healing wounds and sites of
bacterial infections. Several of these conditions are also associated
with increased number of mast cells [6]. In contrast to the effect of
hypoxia on macrophage functions that is well documented [7], the
effect of hypoxia on mast cell functions is poorly investigated.
In this study we have investigated the effect of hypoxia (1% O2)
per se on human mast cell survival, degranulation and cytokine
secretion. In addition, we have analysed the effect of hypoxia on
mast cell reactivity using external factors known to activate mast
cells under certain conditions, i.e., mast cell activation in chronic
inflammation and tumours (CD30 activation) [8], bacteria
membrane component stimulation (LPS) and increase in calcium
(calcium ionophore A23187). One important question to clarify is
if hypoxia is triggering mast cells and if mast cells become
unresponsive to other triggers during hypoxic conditions. Retained
mast cell responsiveness under hypoxia would be of importance for
their protective role in health and disease.
Results
Mast cell survival is sustained under hypoxia
First we investigated the effect of hypoxia (1% O2) on mast cell
viability. We found that cells cultured in hypoxia sustain a high
viability for up to three days. After five days in hypoxia, a
significant drop to 73% viability was observed (P=0.024), which
was further decreased to 47% at day seven (Fig. 1). These results
suggest that CBMC are viable in hypoxia for several days and
consequently data from cells cultured up to five days in hypoxia
should not be biased by cell apoptosis or necrosis.
The effect of hypoxia on mast cell degranulation and
cytokine secretion
We next studied if hypoxia per se induces mast cell degranulation
and release of granule mediators such as tryptase. As shown in
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12360figure 2A we could not observe any increase in the release of
tryptase in cells cultured in hypoxia for 24h compared to
normoxia. We also pre-incubated the cells in hypoxia for 24h
and then transferred them to normoxia to investigate how
reoxygenation for 24h affected the cells. We could not observe
any difference in release of tryptase if cells were pre-treated in
hypoxia compared to normoxia. Thus, hypoxia does not induce
mast cell degranulation by itself (Fig. 2A).
Hypoxia activates HIF-1a which regulates the transcription of
several cytokines and growth factors in, e.g., macrophages [7]. We
therefore measured the effect of hypoxia on cytokine secretion from
mast cells deprived of IL-6 for two days and cultured in hypoxic
conditions for 24 h. The deprivation was performed to avoid
contamination of exogenous added IL-6 to the culture medium. An
antibody array wasused to screen for candidate cytokines that could
be regulated by hypoxia. As shown in figure 2B the spontaneous
secretion of several proteins was reduced by hypoxia, whereas only
IL-6appeared to be induced. The identity of the spots in the arrayis
provided in Table 1. Our results suggest that hypoxia per se induces
secretion of a limited number of cytokines where the secretion of IL-
6 was the most pronounced of those analyzed.
HIF-1a is activated under hypoxic conditions
Under hypoxic conditions several cellular mechanisms can be
activated. The transcription factor HIF-1a is stabilised under low
oxygen concentrations and can thus activate a variety of genes
involved in the control of cellular metabolism. A mast cell derived
cell line, HMC-1.2, and CBMC were cultured for 24h, both under
normoxic and hypoxic conditions. As a positive control, we used
deferoxamide (DFX), which is a well-described stabiliser of HIF-1a.
Both hypoxic conditions and DFX induced an increased accumu-
lation of the HIF-1a protein in both mast cell types tested (Fig. 3).
Autocrine IL-6 promotes mast cell survival in hypoxia
We first confirmed that IL-6 secretion is induced by hypoxia. As
shown in figure 4A, increased levels of IL-6 could be measured in
supernatants from mast cells cultured in hypoxia for 96h, as
compared to normoxia. In addition, other cytokines were analyzed
using a CBA flexkit.The levelsof FGF2,M I P - 1 b,I L - 1 b, angiogenin
and GM-CSF were below the detection limit (data not shown).
VEGF and TNF secretion was not consistent in the different donors
analysed (data not shown). Since IL-6 is a survival factor for human
mast cells [9–11] we next investigated if IL-6 released from hypoxic
mast cells could promote mast cell survival in an autocrine fashion.
Mast cells were deprived of SCF and IL-6 for two days before they
werecultured for 96h inhypoxiaand normoxia inthe presenceofan
IL-6 neutralisation antibody or isotype control. IL-6 neutralisation
induced apoptosis with significantly decreased cell viability in
hypoxia compared to cultures treated with the isotype control
antibody, as assessed by trypan blue exclusion (Fig. 4B) and PI/
Annexin V staining (Fig. 4C). Under normal oxygen conditions, the
neutralizing antibody did not have any effect on cell survival
compared to isotype control (data not shown).
Mast cells retain reactivity to different stimuli during and
after hypoxia
One of the most important features of mast cells is their capacity
to react to different stimuli. Since mast cells are distributed in
tissues that may reach transient hypoxia, we next investigated if
mast cells retained reactivity after hypoxia treatment in vitro.T o
examine if mast cell reactivity is influenced by hypoxia, cells were
subjected to stimuli known to act on different signalling pathways
under three different conditions: 1) stimulation 24 h in normoxia;
2) stimulation 24 h in hypoxia; and 3) incubation 24 h in hypoxia
and then transferred to normoxia and stimulated for 24 hr. The
cells were stimulated with A23187, LPS or CD30, and the release
of tryptase and IL-8 were measured as markers for reactivity
towards stimuli. As shown in figure 5, only A23187 significantly
induced degranulation assessed as release of tryptase compared to
control. There was no difference in A23187 reactivity between
cells stimulated before normoxia, hypoxia or those cultured in
hypoxia for 24 before stimulation in normoxia (Fig. 5).
Mast cells express CD30 ligand/CD153 and we have previously
shown that activation by CD30-Fc fusion protein induces a
Figure 1. Mast cell viability. Survival of CBMC cultured for 1 to 7 days in) normoxia (21% O2) or hypoxia (1% O2). Cell viability was calculated using
trypan blue exclusion. Two different donors, n=4, mean 6 SEM. * p,0-05 and ** p,0.01 compared to day 1.
doi:10.1371/journal.pone.0012360.g001
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control for this experiment we used a CD6-Fc fusion protein. We
also measured the release of IL-8 after treatment with LPS and
A23197. All three stimuli induced IL-8 secretion both in
normoxia, hypoxia and in reoxygenated cultures (Fig. 6). Upon
CD30 and LPS treatment the release was significantly attenuated
in the hypoxic cultures and the reoxygenated cultures, compared
to normoxia (Fig. 6). Thus, although mast cells seem to be less
responsive to activating stimuli after hypoxia and even less
responsive after reoxygenation, as observed from the IL-8 release
data, they are still reactive.
Discussion
Mast cells play important roles in several physiological and
pathological processes [1]. Several chronic inflammations are
associated with an accumulation and activation of mast cells, such
as in asthma, rheumatic diseases and tumours [12–14]. During
Figure 2. Mast cell mediator release. A Mast cell tryptase release before or after hypoxia, three different donors, n=3, mean 6 SEM. B Antibody
array: Protein secretion in response to normoxia and hypoxia. The identity of some of the proteins included in the array is indicated. A complete
description of the array is found in Table 1.
doi:10.1371/journal.pone.0012360.g002
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or intermittent hypoxia. Although this implies that mast cells are
viable and reactive under hypoxic conditions, very little data exists
today that supports this hypothesis [15–17].
Our data suggests that mast cells are unresponsive to transient
hypoxia. First, CBMC were viable for several days in hypoxia
(Fig. 1), secondly there was no spontaneous degranulation in
response to hypoxia (Fig. 2A), and thirdly mast cells were still
reactive to stimuli under hypoxia. This confirms that mast cells are
stable to certain physical environmental changes [18,19]. In order
to exclude that the results were biased by pH differences we also
analysed the pH of the medium in hypoxia and normoxia after
24–96 h and found no differences in pH levels between the two
conditions (data not shown).
In other cell types, persistent hypoxia can result in cell death [20]
or mediate a shift in mediator release and disturb cell functions
[21,22]. In macrophages, hypoxia regulates cell functions in
inflammation and in contrast to our results macrophages respond
rapidly to hypoxia by altering gene expression and release of
cytokines [7].
Our data shows that hypoxia provokes IL-6 secretion in mast
cells (Fig. 2B). IL-6 is important for mast cell proliferation [23] and
to promote human mast cell survival [9,10]. In a previous study,
neutralisation of IL-6 in human lung mast cell cultures significantly
decreased the cell viability after seven days in normoxia [11],
implicating that mast cells may induce their own survival in an
autocrine/paracrine fashion. Further, stimulation with IgE
promoted the survival of human lung mast cells and this relation
was dose dependent and hindered by an anti-IL-6 antibody [11].
In the present study we found that anti-IL-6 treatment of mast
cells in hypoxia decreased their survival. Thus, our data support
previous reports that IL-6 produced by mast cells can act as an
autocrine/paracrine survival factor.
One may expect that hypoxia per se would induce secretion of a
subset of cytokines and growth factors, e.g., those regulated by
HIF-1a. In our study we found an accumulation of HIF-1a when
cells were cultured under hypoxia (fig. 3), but we did not see a
consistent increase in cytokine secretion (fig. 2B). Recently,
interesting data supporting the notion that mast cells are rather
unresponsive to hypoxia was reported, where it was described that
additional signalling pathways are needed to induce HIF-1a
expression in human mast cells [24]. Ionomycin, C5a and
substance P, but not mastoparan, was shown to induce HIF-1a
expression. Furthermore, the induction was dependent on a
calcineurin-NFAT binding site in the HIF1A promoter region for
accumulation of HIF-1a and induction of target genes [24]. This
may explain our low response to hypoxia compared to normoxia
and also the low response in combination with other stimuli.
The only cytokine found to be significantly induced by hypoxia
was IL-6. IL-6 is not a classical hypoxia-induced gene, but is
probably regulated by other transcription factors under hypoxic
conditions. Hypoxia-mediatied induction of IL-6 in myocytes has
been shown to be regulated by NFkB and NF-IL6 [25].
Furthermore, IL-6 was induced in human mast cell line HMC-1
upon treatment with DFX, an induction that was partly inhibited
by pre-treatment with a NFkB-inhibitor [16]. There might also be
other pathways involved in the regulation of cellular responses to
hypoxia. One example is change in redox balance that might effect
the activity of the cells. Another interesting finding is that mast cell
degranulation appears not be affected by redox changes induced
by hypoxia [26]. However, the effect on cytokine synthesis and
secretion has not been studied.
Since mast cells are stable in hypoxia we believe that they may
have an important function in innate responses to inflammation
and bacteria, virus, and parasite infections [27]. Though mast cells
often respond to different stimulus with release of mediators, they
also tend to be very stable to environmental factors that affect
many other haematopoietic cells. For example, both human and
mouse mast cells are unaffected by gamma radiation and can be
activated after radioactive exposure with an equal amount of
release compared to non radiated cells [18]. Thus, mast cells
constitute an important defence mechanism to pathogens even
after radiation. Furthermore, ultraviolet B irradiation had no effect
on release of granulae stored mediators of human mast cells [19].
In line with these data we hypothesise that mast cells are refractory
Table 1. Identity of the spots in the antibody array used in figure 2.
a b cde f ghi j k l m n
1 +ctrl +ctrl +ctrl +ctrl blank Ang BDNF BLC BMP-4 BMP-6 CK b 8-1 CNTF EGF Eotaxin
2 2ctrl 2ctrl 2ctrl 2ctrl blank Ang BDNF BLC BMP-4 BMP-6 CK b 8-1 CNTF EGF Eotaxin
3 Eotaxin-2 Eotaxin-3 FGF-6 FGF-7 Flt-3 Lig Fractalkine GCP-2 GDNF GM-CSF I-309 IFN-c IGFBP-1 IGFBP-2 IGFBP-4
4 Eotaxin-2 Eotaxin-3 FGF-6 FGF-7 Flt-3 Lig Fractalkine GCP-2 GDNF GM-CSF I-309 IFN-c IGFBP-1 IGFBP-2 IGFBP-4
5 IGF-1 IL-10 IL-13 IL-15 IL-16 IL-1a IL-1b IL-1ra IL-2 IL-3 IL-4 IL-5 IL-6 IL-7
6 IGF-1 IL-10 IL-13 IL-15 IL-16 IL-1a IL-1b IL-1ra IL-2 IL-3 IL-4 IL-5 IL-6 IL-7
7 Leptin LIGHT MCP-1 MCP-2 MCP-3 MCP-4 M-CSF MDC MIG MIP-1d MIP-3a NAP-2 NT-3 PARC
8 Leptin LIGHT MCP-1 MCP-2 MCP-3 MCP-4 M-CSF MDC MIG MIP-1d MIP-3a NAP-2 NT-3 PARC
9 PDGF-BB RANTES SCF SDF-1 TARC TGF-b1T G F - b3 TNF-a TNF-b blank blank blank blank blank
10 PDGF-BB RANTES SCF SDF-1 TARC TGF-b1T G F - b3 TNF-a TNF-b blank blank blank +ctrl +ctrl
doi:10.1371/journal.pone.0012360.t001
Figure 3. HIF-1a accumulation under hypoxia. HMC-1.2 and
CBMC were cultured for 24 h under hypoxia or normoxia. HIF-1a
accumulation was determined by western blot. DFX was used as a
positive control. The figure is representative of three independent
experiments.
doi:10.1371/journal.pone.0012360.g003
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mediator secretion.
Hypoxia is related to conditions with limited blood flow as in
inflammatorydiseasessuchasasthmaandjointinflammationbutalso
in tumour progression [4]. Subjects with airway mucous plugging can
reach low oxygen levels downstream in the bronchial tree and
hypoxic conditions in the lung may result in hypertrophy and
increased airway smooth muscle accumulation [21]. For patients with
anactivelungdiseasemastcellsmaybeimportantfortheclearanceof
pathogens. The reactivity of mast cells under low oxygen pressure
would then be essential for host defence under these conditions.
There are also several studies on the role of mast cells in
ischemia and reperfusion injury, e.g., myocardial infarction [28].
Mast cell degranulation has been detected in models of ischemia-
reperfusion models, but this mast cell activation might be a result
of complement activation of mast cells [29]. Thus, in these models
mast cells might not be activated directly by hypoxia or the
reperfusion, but through indirect mechanisms.
As outlined in previous studies, mast cells can be very selective
in their mediator secretion [30] and our results show that this is
also true for stimuli acting on different signalling pathways under
hypoxia. A23187, but neither CD30 nor LPS activation, induced
release of tryptase (Fig. 4). The effect of A23187 was not affected
by hypoxia. Cytokine production was in some cases influenced by
hypoxia in combination with different stimuli. In response to
CD30 and LPS stimulation, the release of IL-8 was decreased in
hypoxia and after reoxygenation compared to normoxia (Fig. 5).
CD30 is expressed in Hodgkin lymphoma, atopic dermatitis and
psoriasis, diseases where mast cells are the predominant cell type
expressing CD153 [8,31]. The effect of hypoxia on CD30-mediated
stimulation was more pronounced compared to the effect on LPS or
A23187 reactivity. This implies that CD30-activation of mast cells
in hypoxic tissues is attenuated in these diseases.
Our results show that mast cells survive and can be activated
during hypoxia. Thus, mast cells retain reactivity to external
triggering factors. This suggests that mast cells can play important
roles in host defence even in a tissue with low oxygen pressure.
Understanding the effect of hypoxia on mast cell functions is
critical to understand the role of mast cells in diseases, such as
cancers and asthma that are affected by hypoxia.
Methods
Preparation of cord blood derived mast cells (CBMC)
Isolation and preparation of cells was performed as previously
described [32]. Briefly, mononuclear cells were isolated from
heparinised human umbilical cord blood. CD34
+ cells were
selected from the mononuclear cells with MACS MicroBeads
(Miltenyi Biotech, Germany) and cultured for 3–5 weeks in
StemPro serum free medium (Invitrogen life technologies, USA)
(week 1, 20 000 cells/ml, following weeks, 2000 00 cells/ml)
supplemented with 10 ng/ml IL-3 (on the first week of culture)
(Peprotech, UK), human recombinant stem cell factor (SCF),
100 ng/ml and 10 ng/ml human recombinant IL-6 (both kindly
provided by Amgen, Thousand Oaks, USA). When cells were
.95% tryptase positive they were transferred to RPMI 1640
medium (Sigma, USA) with supplements including heat inactivat-
ed FCS (10%), SCF (100 ng/ml) and IL-6 (10 ng/ml) and kept at
a1 610
6 cells/ml cell density. Medium was changed weekly and
these cells were designated as cord blood derived mast cells
(CBMC). Cultures were kept in 37uC, 5% CO2 and 1% (hypoxia)
or 21% (normoxia) O2 (Sanyo incubator). For all treatments, cells
were cultured in 24 well plates before collection of supernatants
and cell analysis. If nothing else stated, cells were stimulated in
RPMI medium with supplements including 10% FCS.
Culture of HMC-1.2 cells
The human mast cell line HMC-1.2 cells was maintained as
previously described [33]. Briefly, cells were kept in IMDM, L-
glutamine (HyClone, South Logan, UT, USA) medium supple-
mented with 10% heat-inactivated FCS (Life Technologies,
Paisley, UK), a-monothioglycerol, 100 IU/ml penicillin and
50 mg/ml streptomycin (Sigma).
Cell death detection
Cell viability and apoptosis were analysed by trypan blue
exclusion and/or by fluorescence-activated cell sorting (FACS)
using propidium iodide (PI) and FITC-conjugated Annexin V
(Becton Dickinson, Sweden) staining of cells. Data was analysed by
Figure 4. IL-6 is a mast cell survival factor. A Mast cell IL-6
secretion after 96 h culture in hypoxia. B–C Mast cell viability after 96 h
culture in hypoxia as analysed with B trypan blue exclusion (B) and
Annexin V, PI staining (C). Cells were treated with a neutralising anti-IL-6
or isotype control antibody (1.0 ug/ml). n=3, mean 6 SEM.** P,0.01,
*** P,0.001.
doi:10.1371/journal.pone.0012360.g004
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calculated as percent of total cell amount.
Western blot
CBMC and HMC-1.2 were cultured for 24h under normoxia or
hypoxia at 1610
6 cells/ml cell density, total cells 4610
6.A sa
positive control, cells were treated with 100 mM DFX (Sigma).
Cells were lysed using 100 ml of a solution of SDS+DTT. Samples
were loaded on a NuPage 4–12% Bis-Tris gel (Invitrogen) and run
for 1h at 200 V. Gel was blotted to a Hybond-ECL nitrocellulose
membrane (Amersham, Sweden). Membrane was blocked with
5% fat-free milk in TBS-T 0.1% for 1h at room temperature,
Figure 5. Mast cell degranulation. Tryptase release 24 h after stimulation in response to different stimuli. Cells were cultured in 24 well plates and
treated with stimuli in normoxia, hypoxia or after hypoxia for 24 h. Supernatants were analysed for the content of tryptase in three different donors,
n=3, mean 6 SEM.
doi:10.1371/journal.pone.0012360.g005
Figure 6. IL-8 secretion. IL-8 release 24 h after stimulation in response to different stimuli. Cells were cultured in 24 well plates and treated with
stimuli in normoxia, hypoxia or after hypoxia for 24 h and then transferred to normoxia and stimulated for 24 h. Supernatants were analysed for the
content of IL-8 in three different donors, n=3, mean 6 SEM and
* P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0012360.g006
Mast Cells and Hypoxia
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(Novus Bio, UK) 1:500 in TBS-T-5% BSA solution. Protein was
detected using Lumiglo (Cell Signalling Technology) and lumi-
nescence detected using Hyperfilm-ECL (Amersham).
Analysis of degranulation
To assess the degree of degranulation, the release of tryptase
was measured by ImmunoCAP
TM (Phadia AB, Uppsala, Sweden).
Antibody array
Secretion of multiple cytokines in cell supernatants was detected
by human cytokine antibody Arrays VI and VII (Chemicon,
Sweden). Briefly, cell supernatants were added to a solid array
membrane coated with antibodies against specific cytokines. All
cell incubations were performed with 0.2% BSA instead of serum
for minimisation of false positive data. A biotin conjugated
primary antibody together with HRP-Streptavidin substrate was
used for detection of analytes. The membranes were exposed to x-
ray film and detected by a chemiluminescence imaging system. A
complete description of the cytokines analyzed with the antibody
array can be found in Table 1.
Analysis of cytokines and chemokines
Cell supernatants were analysed with ELISA for the content of
IL-8 (BioSource, Camarillo, USA) and IL-6 (R&D systems,
Stockholm, Sweden). The assays were performed with a double
sandwich ELISA as described by the manufacturer. A CBA flex set
assay of seven different beads detecting cytokines and chemokines
(FGF2, MIP-1b, IL-1b, VEGF, TNF, angiogenin and GM-CSF)
was used (Becton Dickinson, Sweden). Preparation of beads was
performed according to manufacturer’s instructions. Data was
collected with FACSAria and analysis was performed with
FACSDiva and FCAPArray software (Beckton Dickinson).
Neutralisation of IL-6
Cells were cultured in RPMI with supplements but without IL-
6, or without IL-6 and SCF, for two days before further treatment.
After two days, soybean protease inhibitor (100 mg/ml, Sigma-
Aldrich, Sweden), anti-human IL-6 (1.0 mg/ml, R&D systems,
Sweden) or IgG1 isotype control (1.0 mg/ml) were added. Cells
were incubated for 24, 48 and 96 h in hypoxia or normoxia.
Treatment with CD30, CD6, LPS and A23187
Cells were treated with immobilized CD30 (10 mg/ml), or CD6
(10 mg/ml, R&D systems), LPS (1 mg/ml, Sigma-Aldrich) or
A23187 (0.5 mM, Sigma-Aldrich) for 24 h. All reagents were
dissolved in PBS or dH2O with the exception of A23187 which
was used with a maximum of 0.5% DMSO. Cells were cultured in
supplemented RPMI with 0.2% BSA.
Statistical analyses
SigmaStat software was used to perform the statistical analysis.
Comparisons between more than two groups were made with
parametric tests (One Way Repeated Analysis of Variance).
Further pair wise comparisons were performed with a student’s
paired t-test. Difference was regarded as significant if P,0.05. All
data are expressed as mean 6 SEM.
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